Raydiant Oximetry, Inc.
Raydiant Oximetry, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Raydiant Oximetry, Inc..
Raydiant Oximetry, Inc. is a company.
Key people at Raydiant Oximetry, Inc..
Key people at Raydiant Oximetry, Inc..
Raydiant Oximetry, Inc. is a clinical-stage medical device company developing Lumerah™, a noninvasive fetal pulse oximeter that directly measures oxygen levels in fetal blood from the mother's abdomen to detect distress during labor and improve outcomes for mothers and babies.[1][2][3][6] It serves obstetric providers and hospitals, addressing limitations of current electronic fetal monitoring, which has led to a 6-fold increase in U.S. cesarean deliveries over 50 years without reducing neonatal injuries, stillbirths, or cerebral palsy.[3] The company has raised over $8.2 million in funding, completed an Early Feasibility Study in October 2025, initiated an IDE Pilot Study in November 2025, and secured FDA Breakthrough Device status for accelerated approval, positioning it for market entry after a projected 10-year, $30 million development journey.[1][2][3]
Founded in 2015 by Neil P. Ray, MD, an anesthesiologist practicing since 2005, Raydiant Oximetry emerged from Ray's clinical observations of unmet needs in labor and delivery monitoring.[1][2] Lacking engineering or business expertise, Ray pitched his idea to the Fogarty Institute for Innovation, a Bay Area nonprofit medical device accelerator, which provided crucial early support.[1] The company built on established pulse oximetry technology—highlighted during COVID-19 for skin tone accuracy issues—to create a fetal-specific solution, securing initial SBIR funding and grants like $3 million from the Irish government.[1][3] Pivotal early traction included a $5.6 million Series A led by VCapital and graduation from Fogarty, fueling preclinical trials showing improved distress detection.[1][3]
Raydiant rides the wave of precision maternal-fetal medicine, leveraging biophotonics, AI-driven signal processing, and noninvasive wearables to overhaul 50-year-old fetal monitoring amid U.S. maternal mortality crises and global childbirth risks.[1][3] Timing aligns with post-COVID scrutiny of pulse oximetry biases, heightened investor interest in women's health (e.g., Series B kickoff via March of Dimes), and regulatory support like FDA Breakthrough designation.[1][3] Market forces favor it: demand for better distress detection to cut cesareans (now over 30% in the U.S.), grants from Gates Foundation and governments signal public health priority, and collaborations like GE HealthCare amplify scale.[3] By succeeding, Raydiant could influence ecosystems, drawing capital to women's and children's health tech, where unmet needs persist despite critical stakes.[1]
Raydiant is poised for Series B expansion and pivotal trials post-2025 milestones, targeting market entry in 3-5 years with $20 million more needed to hit $30 million total investment.[1][3] Trends like AI-enhanced diagnostics, equitable medtech (addressing skin tone issues), and global health equity will propel it, especially via partnerships and grants.[1][3] Its influence may evolve from pioneer to standard-of-care setter, lifting investment tides for maternal innovations and safer births worldwide—transforming Ray's bedside insight into a tide-rising success.[1]
